MS and EBV: Two clinical trials launch in Australia
Is targeting EBV the key to treating MS? Two new clinical trials are testing antiviral therapies to slow progression and reduce fatigue.
How the strongest MS risk gene alters the immune response to Epstein-Barr virus
A new study has revealed that an MS risk gene changes how the immune system responds to EBV, linking these two major risk factors.
AHSCT awakens EBV in MS, yet relapse remains at bay
The first study of EBV immunity shows reactivation of the virus after AHSCT is not related to relapses in MS.
Does Epstein Barr virus in early MS bias the immune system towards brain inflammation?
A new study seeks to understand the role of B cells and EBV in the development of MS.
New links between B cells and EBV infections in women with MS
New Australian research has shed light on unique changes in B cells in women with MS, creating avenues for understanding why MS affects more women than men.
EBV infection and MS risk genes work together to facilitate MS
New Australian research has found a link between EBV infection and MS risk genes which will enhance understanding of the role of EBV at a cellular level.
Anti-EBV trial results explained by Professor Michael Pender
Professor Michael Pender explains more about the anti-EBV treatment 'adoptive T cell immunotherapy' that has shown promise for people with progressive MS in his clinical trial.
Anti-EBV trial shows promise in progressive MS
World-first clinical trial shows new anti-EBV treatment appears safe and may help progressive MS.